Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea

Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea

Background and aims: The present study aimed to compare the levels of the inflammatory biomarkers of fibrinogen and high-sensitivity C-reactive protein (hs-CRP) among type 2 diabetic patients treated with empagliflozin and other hypoglycemic drugs. Methods: This cross-sectional study was performed o...

Full description

Bibliographic Details
Main Authors:	Pegah Mohaghegh, Mohammad Reza Rezvanfar, Farideh Jalali-Mashayekhi, Zahra Amerei, Mohammad Hosseinzadeh
Format:	Article
Language:	English
Published:	Shahrekord University of Medical Sciences 2023-10-01
Series:	Journal of Shahrekord University of Medical Sciences
Subjects:	empagliflozin fibrinogen high-sensitivity c-reactive protein inflammatory factors sodium-dependent glucose cotransporter 2 inhibitor type 2 diabetes
Online Access:	https://j.skums.ac.ir/PDF/jskums-25-189.pdf

Similar Items

Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review
by: Sopak Supakul, et al.
Published: (2022-06-01)

Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
by: Marta Brandão Calçada, et al.
Published: (2021-04-01)

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
by: Ellen Vercalsteren, et al.
Published: (2024-02-01)

Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice
by: Yimin Tu, et al.
Published: (2022-12-01)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
by: Genlong Xue, et al.
Published: (2022-10-01)

Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort
by: Jaehyun Lim, et al.
Published: (2024-02-01)

Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
by: Оksana S. Fuks, et al.
Published: (2023-07-01)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
by: Ito H, et al.
Published: (2019-09-01)

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
by: Simke W. Waijer, et al.
Published: (2020-09-01)

Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model
by: Chang Chu, et al.
Published: (2022-09-01)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
by: Nguyen Ngoc Trang, et al.
Published: (2021-01-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

SGLT2-Inhibitors and Euglycemia Diabetic Ketoacidosis: A Missed Diagnosis
by: Muhammad Nadeem Ahmed Khan, et al.
Published: (2023-12-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis
by: Mobin Mohammadtabar, et al.
Published: (2023-03-01)

Empagliflozin Use and Fournier’s Gangrene: Case Report and Systematic Literature Review
by: Mario Antunes, et al.
Published: (2021-05-01)

Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis
by: Cheng-Chih Chung, et al.
Published: (2023-02-01)

Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
by: Dae Jung Kim, et al.
Published: (2023-03-01)

Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study
by: Kenta Okada, et al.
Published: (2021-04-01)

The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
by: Wael Abu Dayyih, et al.
Published: (2024-03-01)

Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study
by: Mayada M. Samkari, et al.
Published: (2023-06-01)

Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
by: Takeshi Horii, et al.
Published: (2023-11-01)

Short-Term Effect of Sodium Glucose Co – Transporter 2 Inhibitors on Routine Laboratory Examinations
by: Osman İnan, et al.
Published: (2022-07-01)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
by: Muhammad Shahzeb Khan, et al.
Published: (2023-01-01)

Association between Empagliflozin Use and Electrocardiographic Changes
by: Daniel Antwi-Amoabeng, et al.
Published: (2022-07-01)

Cost‐Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States
by: Odette S. Reifsnider, et al.
Published: (2024-02-01)

Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta‐analysis
by: Yinyuan You, et al.
Published: (2023-10-01)

Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy
by: Edoardo Mannucci, et al.
Published: (2022-12-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
by: Alfredo Caturano, et al.
Published: (2023-01-01)

Real‐world risk of lower‐limb amputation associated with sodium–glucose cotransporter 2 inhibitors versus metformin: A propensity score‐matched model analysis in Japan
by: Gen Mizutani, et al.
Published: (2022-12-01)

Administration of sodium-glucose cotransporter-2 inhibitors in kidney transplant patients with diabetes: a systematic review and meta-analysis
by: Hamidreza Khodabandeh, et al.
Published: (2023-09-01)

Glucose Transporters as a Target for Anticancer Therapy
by: Monika Pliszka, et al.
Published: (2021-08-01)

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
by: Jun Sung Moon, et al.
Published: (2023-01-01)

Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction
by: Toru Kawada, et al.
Published: (2023-09-01)

Acute effects of empagliflozin on open-loop baroreflex function and urine glucose excretion in Goto-Kakizaki diabetic rats
by: Toru Kawada, et al.
Published: (2023-04-01)

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction
by: Oscar Eduardo Ospina González, et al.
Published: (2023-01-01)

SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN
by: Aisha Sheikh, et al.
Published: (2021-11-01)

Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study
by: Hao‐Chih Chang, et al.
Published: (2024-04-01)